Elite control of HIV: is this the right model for a functional cure?

Leslie R. Cockerham and Hiroyu Hatano

HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA, USA

A cure for HIV is still greatly needed and has become a global research priority. A unique subset of HIV-infected individuals who spontaneously control HIV exists, and these are known as ‘elite controllers’. They may represent a natural model for a ‘functional cure’ in which there is long term control of viral replication and remission from symptoms of HIV infection in the absence of antiretroviral therapy. However, controllers have evidence of ongoing inflammation, CD4+ T cell depletion, and perhaps even inflammation-associated cardiovascular disease, suggesting that this natural long term virologic control may be coming at an immunologic and clinical cost. These individuals may continue to provide continued insights into mechanisms of host control; however, they may not represent the best model of a functional cure, if we believe that a cure should require a disease-free (and not just a treatment-free) state.

HIV cure is a research priority

The use of antiretroviral therapy (ART) has resulted in the marked decline in the morbidity and mortality associated with HIV infection for individuals with access to therapy [1,2]. Many antiretroviral-treated individuals achieve substantial reconstitution of CD4+ T cell counts and near-complete suppression of viral replication. However, despite this achievement, ART is not curative. Interruption of therapy results in the rapid rebound of viral replication in most HIV-infected individuals due to the presence of a long-lived infected cell population that harbors replication-competent virus known as the latent viral reservoir (see Glossary) [3]. Furthermore, even in those individuals who are successfully treated, ART does not fully restore health or normal immune function as HIV-infected individuals still experience increased non-AIDS-related morbidity and mortality compared to HIV-uninfected individuals [4–7]. Lastly, there are still a large number of individuals who do not have access to ART, which contributes to morbidity and subsequent transmission events [8,9]. Therefore, there is a great need for a cure for HIV infection and this has become a global research priority [10].

A cure may be feasible and elite controllers may be a potential model for functional cure

The case of the ‘Berlin patient’ has provided evidence to suggest that a cure for HIV infection may be possible in some individuals [11]. The Berlin patient is thought to have achieved a ‘sterilizing cure’ given that no replication-competent virus has been found, despite vigorous study several years after the discontinuation of ART [12,13]. The circumstances which led to this apparent cure were incredibly unique, however, because this patient: (i) was heterozygous for the CCR5 delta-32 (Δ32) deletion at baseline (a genetic factor known to confer a favorable HIV disease course); (ii) received an extensive conditioning regimen that included whole body irradiation to deplete the hematopoietic system; (iii) received two allogeneic bone marrow transplants from a donor who was homozygous for the CCR5 Δ32 deletion; (iv) exhibited graft-versus-host disease (and perhaps as a consequence ‘graft-versus-HIV-reservoir responses’); and (v) received immune-modulating therapies after transplant. It is unclear whether one, or all, of these factors was necessary to achieve a sterilizing cure. Furthermore, many of the interventions in this unique case have substantial risks associated with them, making this scenario difficult to replicate in a wider population. A sterilizing cure, therefore, is likely to be more difficult to achieve and may not be possible for most HIV-infected individuals.

There exists a population of HIV-infected individuals who spontaneously control their virus, termed ‘HIV controllers’. This group may represent a natural model for a ‘functional cure’ in which there is long term control of viral replication and remission from symptoms of HIV infection in the absence of ART. It is likely that a functional cure will be more feasible than a sterilizing cure. Understanding the

---

**Glossary**

**Elite controller:** a subset of HIV-infected individuals who maintain plasma viral loads to levels below the limits of clinical detection (<50–75 copies/ml) in the absence of anti-retroviral therapy.

**Functional cure:** long term host control of viral replication and remission from symptoms of HIV infection in the absence of ART, but replication-competent HIV remains detectable.

**Latent viral reservoir:** an HIV-infected cell population that harbors integrated, replication-competent HIV virus.

**Long term nonprogressors (LTNP)s:** individuals with long term clinical and immunologic stability, usually over a period of several years, in the absence of ART. These individuals may or may not have a low HIV plasma viral load as there is usually no viral load requirement in this definition.

**Sterilizing cure:** complete eradication of replication-competent HIV from the body.
biologic mechanisms of HIV control is an area of intense research focus as it may inform future therapeutic strategies.

Defining elite control
HIV controllers are HIV-infected individuals who, in the absence of therapy, are able to maintain low levels of plasma HIV RNA. They are often distinct from 'long term nonprogressors' (LTNPs) who are generally defined as untreated individuals who have long term clinical and immunologic stability over a period of several years, without a viral load requirement. The term 'elite controllers' usually refers to the subset of controllers who maintain plasma viremia to levels below the limits of clinical detection (<50–75 copies/ml). This a rare group, comprising <1% of the HIV-infected population [14]. There is an over-representation of certain MHC class 1 alleles in elite controllers, including class I HLA-B*57 and HLA-B*27 alleles [15–17]. Enrichment of specific natural killer (NK) cell immunoglobulin-like receptors (KIR) has also been seen in one study of LTNPs [18], although this finding was not seen in a small cohort of elite controllers [19]. These data argue that sustained host immune responses are a mechanism by which virus is controlled in these individuals. However, not all HIV controllers possess these protective alleles, and some individuals with favorable genetics have normal progression of disease, suggesting that these genetic factors are neither necessary nor sufficient for immune control [20]. Thus, elite controllers are likely a heterogeneous group with multiple potential mechanisms of control and this group of individuals provides a unique opportunity to better understand viral persistence and host control.

Potential mechanisms of viral control
The precise mechanism of viral control in elite controllers is unknown and may be multifactorial with different factors playing a role in different individuals [21]. Host genetics and how they shape the response of the different arms of the immune system: adaptive, innate, and intrinsic, are all possible areas in which elite controllers may have unique ways to maintain control of viral replication (Figure 1).

One potential mechanism of control is the CD8+ T cell response. The presence of specific MHC class I alleles has been one of the most consistent factors associated with host control. It may be that CD8+ cytotoxic T lymphocytes (CTLs) restricted by the class I molecules such as HLA-B*57 and HLA-B*27 are more potent and polyfunctional [22–24]. Previous studies have found that although the frequency of HIV specific CD8+ CTLs is not elevated in elite controllers [25], their CTLs seem to produce more cytolytic proteins, such as perforin and granzyme B, [23,26] and more pro-inflammatory cytokines, including interleukin (IL-2) and interferon-gamma (IFN-γ) [24]. However, a strong CTL response is unlikely to be the only factor leading to viral control, as elite controllers have been shown to maintain viral suppression even in the setting of viral escape mutations [27].

The role of antibodies in achieving viral suppression in elite controllers is unclear. Several studies have shown that the levels of neutralizing antibodies (antibodies that bind to the HIV envelope and block viral entry into target cells) are either similar or lower in elite controllers compared to viremic individuals [28,29]. However, antibodies could also contribute to viral control via antibody-dependent cell-mediated cytotoxicity (ADCC). In ADCC, cells coated with antibodies are destroyed by NK cells. It is unclear, however, whether elite controllers have increased ADCC activity, as studies have had conflicting results [28,30].

Another mechanism by which elite controllers may achieve viral suppression is via the innate immune system. HLA class I molecules can also bind to KIRs that are expressed by NK cells. HLA-B*57 is a Bw4 allele, which is a natural ligand for several KIRs including KIR3DS1 and KIR3DL1, and this combination has been associated with delayed progression to AIDS in noncontrollers [31,32]. It is possible that this relationship is explained by linkage disequilibrium with HLA-B alleles, but a previous study found that these KIRs were enriched in a population of LTNPs who did not possess the HLA-B*57 allele [18]. NK cells expressing the KIR3DS1 allele strongly inhibit HIV replication in target cells in vitro and may be a mechanism of elite control apart from its association with HLA-B alleles [33]. Further studies are needed to better understand the contribution of KIRs to viral control in elite controllers.

The intrinsic immune system may also play a role in the control of HIV in elite controllers. Cell-intrinsic mechanisms, such as restriction factors, can limit HIV’s ability to replicate in target cells and could theoretically lead to control of plasma viremia. However, one study which looked at one of the most well-characterized restriction factors, APOBEC3G, did not find a higher frequency of hypermutated proviral genomes in elite controllers compared to ART-treated individuals, suggesting that enhanced APOBEC activity alone could not account for the control of viral replication in elite controllers [34]. Another recent study examined 34 anti-HIV host restriction factors and did not find an increase in the overall expression of restriction factors in elite controllers [35]. However, a single factor, schlafen 11, was expressed at a significantly higher level in CD4+ T cells from elite controllers compared to both untreated and ART suppressed subjects. It may be that the expression of specific host restriction factors, rather than the overall frequency of expression, is important for viral control. Additional examination of restriction factors could lead to the development of curative strategies.

Translating mechanisms of viral control to cure research
There are potentially several factors that allow elite controllers to maintain undetectable viral loads and that may be relevant for future research. These factors include CD8+ CTL responses, KIRs, and intrinsic restriction factors. Eliciting strong CTL responses will likely be a part of future cure strategies. Recent cure efforts have focused on reactivation strategies; however, a recent study found that reactivation alone in the presence of autologous CD8+ T cells did not result in effective killing [36]. Prestimulation of CD8+ T cells or using CTLs from elite controllers
resulted in improved killing. Less is understood about antibodies, KIRs, and restriction factors and further studies will be needed to better understand their role in viral control and potentially apply this to the cure effort.

**Elite control but not cure**

Although elite controllers have undetectable viremia by standard clinical assays, when using more sensitive assays for RNA detection in the plasma, almost all elite controllers have detectable levels of plasma viremia [37,38] and viral ‘blips’ of >50 copies/ml occur in controllers [37,39]. Previous studies have detected HIV RNA and DNA in peripheral blood mononuclear cells (PBMCs) [40] and shown that virus from controllers is replication-competent [41,42] and has no substantial genetic defects [43]. Furthermore, there is evidence of ongoing viral replication in HIV controllers based on the presence of genetic viral divergence over time [44,45]. Elite controllers also have detectable levels of HIV RNA and DNA in rectal cells [46], although levels are lower than HIV-infected individuals on ART. Therefore, it seems clear that even though elite controllers maintain low levels of plasma RNA, HIV virus is easily detectable in most controllers and is likely to be replication-competent.

**Ongoing viral replication and immune control may have consequences**

There is growing evidence to suggest that ongoing viral replication, even at low levels, may have detrimental immunologic consequences. Markers of T cell activation (CD4+ and CD8+ T cells co-expressing HLA-DR and CD38), inflammation and coagulation (e.g., interleukin-6 and D-dimer) and microbial translocation (e.g., soluble CD14) have all been associated with increased morbidity and mortality in HIV infection [47-50]. Although elite controllers maintain viral loads under the limit of detection, they too have elevated levels of CD4+ T cell activation compared to HIV-uninfected individuals and higher CD8+ T cell activation compared to both HIV-uninfected as well as HIV-infected persons with viral suppression on ART [51,52]. One study also found that elite controllers had significantly higher levels of D-dimer and soluble tissue factor, compared to both HIV-negative controls and ART-suppressed HIV-infected individuals [53]. Elevated levels of soluble CD163 have also been observed in elite controllers [54]. They also have increased levels of lymphoid tissue fibrosis compared to people uninfected with HIV [55]. It is possible that continued exposure to virus, albeit at low levels, results in the production of inflammatory cytokines, elevated levels of T cell activation and coagulation factors, and ongoing damage to areas such as the mucosal surfaces of the gastrointestinal (GI) tract, vascular endothelium and lymphoid tissue.

This increased immune activation and inflammation may affect clinical outcomes as well. Despite the lack of detectable viremia by clinical assays and the lack of exposure to ART which, theoretically, could have cardiovascular side effects, elite controllers have higher levels of coronary atherosclerosis, as measured by carotid artery intima media thickness (IMT) and coronary computed tomography angiography (CTA), compared to HIV-uninfected individuals [54,56]. Although further studies are needed, these data suggest that the increased inflammation in controllers may have clinically relevant consequences and contribute to nonAIDS morbidity and mortality. Lastly, a small proportion of HIV controllers progress immunologically despite maintaining low plasma RNA levels, and this decline in CD4+ T cell count is associated with T cell activation [51]. This observation raises the possibility that, even in the absence of measurable plasma viremia, a mechanistic link

---

**Figure 1.** Mechanisms of host viral control may have both beneficial and negative effects for elite controllers. Potential mechanisms of host control of plasma viremia are noted in the blue box. These factors may have beneficial effects for these individuals (green box). However, there may also be immunologic consequences of the immune response that lead to inflammation and viral persistence (red box).

<table>
<thead>
<tr>
<th>Beneficial effects</th>
<th>Negative effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Control of plasma viremia</td>
<td>• Production of pro-inflammatory cytokines</td>
</tr>
<tr>
<td>• Maintenance of CD4+ T cell counts in most individuals</td>
<td>• Lymphoid fibrosis</td>
</tr>
<tr>
<td>• Decreased size of latent reservoir</td>
<td>• Mucosal damage</td>
</tr>
<tr>
<td></td>
<td>• Continued seeding of latent reservoir</td>
</tr>
<tr>
<td></td>
<td>• Maintenance of latency</td>
</tr>
</tbody>
</table>

**Elite controllers**

- Potency of HIV-specific CD8+ T cell responses
- T cell activation
- Expression of specific restriction factors
- Enrichment of specific NK cell receptors
may exist between chronic inflammation and progressive immunodeficiency.

**Elite controllers may benefit from ART**

Given the concern that even very low levels of viral replication may lead to disproportionately high levels of immune activation and inflammation (which, in turn, may lead to an increased risk of AIDS and nonAIDS defining events), a prospective study of ART initiation was recently conducted in a cohort of asymptomatic HIV-infected controllers, including four elite controllers [57]. Participants were treated with an antiretroviral regimen of raltegravir and tenofovir/emtricitabine for 24 weeks and underwent blood collection and, in some instances, colorectal biopsies. Despite having low plasma HIV RNA levels at baseline before starting ART, controllers had an early and persistent decrease in ultra-sensitive plasma HIV RNA levels and HIV antibodies levels. Controllers also had a significant decrease in the percentage of CD4\(^+\) and CD8\(^+\) T cells co-expressing HLA-DR and CD38 as well as programmed death-1 (PD-1) in PBMCs. In the rectum, controllers had a decrease in CD8\(^+\) T cell activation. This study showed that antiretroviral therapy in controllers leads to significant decreases in ultrasensitive plasma and rectal HIV RNA, as well as markers of immune activation/dysfunction in blood and gut.

Even in the subset of the four elite controllers, a significant decrease in ultrasensitive plasma HIV RNA levels was seen after the initiation of ART [57]. Similarly, this subset of controllers had a decrease in HIV antibody levels. There was also a trend toward decreased levels of immune activation in CD8\(^+\) T cells in these four elite controllers. These data suggest that, even in the subset of elite controllers who maintain undetectable HIV viral loads, HIV replication persists and contributes to a chronic inflammatory state.

Another recent study treating three elite controllers and one viremic controller with the same antiretroviral regimen for 9 months found >1 log decrease in the frequency of CD4\(^+\) T cells carrying replication-competent HIV in three out of four subjects after the initiation of ART [58]. Interestingly, after the discontinuation of therapy, levels rebounded back to their pre-ART baseline.

Collectively, these studies provide further support that elite controllers harbor replication-competent virus and that residual viral replication is occurring in the absence of ART, despite undetectable plasma RNA levels. The data also suggest host rather than virologic factors account for the remarkable degree of viral control in these unique individuals. Furthermore, the decrease in markers of immune activation with the addition of ART suggests that there may be immunologic consequences to even very low levels of viral replication (Figure 1). It is still unclear, however, whether the initiation of ART in elite controllers would provide clinical benefits that outweigh any adverse effects associated with antiretroviral drugs. A larger study examining the effect of ART on immunologic and virologic parameters in controllers is currently underway.

**Concluding remarks**

Elite controllers are a rare group of individuals who control viral replication in the absence of ART and are thought to potentially represent a model for a functional cure. Recent studies of these individuals have shown that a complete block of viral replication is not necessary to achieve long term virologic control. However, the evidence also suggests that the immune responses that allow elite controllers to limit viral replication may also result in increased inflammation and immune activation, leading potentially to negative clinical consequences (Figure 1). In other words, this natural long term virologic control appears to be coming at an immunologic and/or clinical cost. This is not to say that further study of controllers is unwarranted. Additional study of these individuals may provide continued insights into mechanisms of host control that could inform future therapeutics (Box 1). Understanding why some mechanisms of control are associated with negative inflammatory consequences is also an important issue. It may be, however, that untreated HIV-infected controllers may not represent the best model of a functional cure, if we believe that a cure should require a disease-free (and not just a treatment-free) state.

**Box 1. Outstanding questions**

- What mechanism(s) allow elite controllers to maintain undetectable HIV viral loads?
- Can these mechanisms of virologic control be induced in noncontrollers and result in a functional cure?
- What are the immunologic consequences of host viral control?
- Would elite controllers benefit from antiretroviral therapy?

**References**


18 Jiang, Y. et al. (2013) KIR3DS1/L1 and HLA-Bw4-801 are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. *BMC Infect. Dis.* 13, 405


20 Emu, B. et al. (2008) HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. *J. Virol.* 82, 5398–5407


52 Hunt, P.W. et al. (2011) A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. *PLoS ONE* 6, e15924


55 Sanchez, J.L. et al. (2014) Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy, but may be reversible with curative interventions. *J. Infect. Dis.* Published online October 24, 2014. (http://dx.doi.org/10.1093/infdis/jiu586)

